Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological...

Related Keywords

United States ,Paul Stoffels ,Johnson ,Guillain Barr ,Mathai Mammen ,Janssen Biotech Inc ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Janssen Research Development ,European Commission On ,Centers For Disease ,None Of The Janssen Pharmaceutical Companies ,Drug Administration ,World Health Organization ,Advisory Committee On Immunization Practices ,National Immunization Technical Advisory Groups Nitags ,Exchange Commission ,Companies Of Johnson ,Products Advisory Committee ,Strategic Advisory Group Of Experts ,Related Biological Products Advisory Committee ,Emergency Use Authorization ,Vice Chairman ,Executive Committee ,Chief Scientific Officer ,Global Head ,Janssen Research ,National Immunization Technical Advisory Groups ,Disease Control ,Advisory Committee ,Immunization Practices ,Conditional Marketing Authorization ,European Commission ,Emergency Use Listing ,Strategic Advisory Group ,Low Levels ,Adverse Event Reporting System ,Janssen Biotech ,Fact Sheet ,Healthcare Providers Administering Vaccine ,Vaccination Providers ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Johnson Amp ,